Antibodies to programmed cell death–1 (PD-1) such as nivolumab have shown promising clinical activity in patients with advanced non–small cell lung cancer (NSCLC), but their efficacy appears to be less pronounced in patients with such tumors harboring epidermal growth factor receptor gene (EGFR) mutations. Recent findings suggest that patients with EGFR mutation–positive NSCLC who develop resistance to tyrosine kinase inhibitors (TKIs) due to mechanisms other than acquisition of the secondary T790M mutation of EGFR are more likely to benefit from nivolumab treatment, possibly as a result of a higher level of expression of the PD-1 ligand PD-L1, than are T790M-positive patients.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rSHCvZ
via IFTTT
Τετάρτη 24 Μαΐου 2017
A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for patients with EGFR mutation–positive nonsquamous non–small cell lung cancer who acquire resistance to tyrosine kinase inhibitors not due to a secondary T790M mutation: rationale and protocol design for the WJOG8515L study
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cancer is associated with genomic instability and aging. Genomic instability stimulates tumorigenesis, whereas deregulation of oncogenes acc...
-
Eribulin is one of the newer chemotherapeutic agents approved for use in later line treatment of patients with metastatic breast cancer. Pha...
-
Abstract Helmet manufacturers recommend replacing a bicycle helmet after an impact or after anywhere from 2 to 10 years of use. The goal o...
-
Publication date: 10 June 2017 Source: Journal of Controlled Release, Volume 255 Author(s): Ožbej Zupančič, Andreas Bernkop-Schnürch Pept...
-
Publication date: 10 June 2017 Source: Journal of Controlled Release, Volume 255 Author(s): Chad S. Cummings, Katherine Fein, Hironobu Mur...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
<span class="paragraphSection"><div class="boxTitle">Abstract</div>It is not clear whether breast canc...
-
Abstract Varroa destructor is one of the scourges of global beekeeping. It was detected for the first time in Benin in 2011 on the honeyb...
-
Hydroxyurea (HU) has a long history of clinical and scientific use as an antiviral, antibacterial, and antitumor agent. It inhibits ribonucl...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου